Skip to content
  • Partnerships
  • News
  • Contact
Fore Biotherapeutics
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
Search
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Partnerships
  • News
  • Contact

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer


August 15, 2021 1:07 PM EDT

Read More

Press Release May 19 2021 Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments Read more
Press Release May 10 2021 Fore Biotherapeutics Opens 
U.S. Headquarters in Philadelphia’s Biotech Hub Read more
Press Release Apr 29 2021 High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds Read more
Fore Biotherapeutics logo
  • Science
    • Plixorafenib Program
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Pipeline
  • Partnerships
  • News
  • Contact
  • Visit us on Twitter
  • Visit us on Linked In
©2025 Fore Biotherapeutics US Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy